首页> 外文期刊>Cancer gene therapy >Identification of folate receptor (FR) binding oligopeptides and their evaluation for targeted virotherapy applications
【24h】

Identification of folate receptor (FR) binding oligopeptides and their evaluation for targeted virotherapy applications

机译:鉴定叶酸受体(FR)结合寡肽及其对靶向病毒疗法的评价

获取原文
           

摘要

Oncolytic virotherapies (OV) based on human adenoviral (HAdV) vectors hold significant promise for the treatment of advanced ovarian cancers where local, intraperitoneal delivery to tumour metastases is feasible, bypassing many complexities associated with intravascular delivery. The efficacy of HAdV-C5-based OV is hampered by a lack of tumour selectivity, where the primary receptor, hCAR, is commonly downregulated during malignant transformation. Conversely, folate receptor alpha (FR) is highly expressed on ovarian cancer cells, providing a compelling target for tumour selective delivery of virotherapies. Here, we identify high-affinity FR-binding oligopeptides for genetic incorporation into HAdV-C5 vectors. Biopanning identified a 12-mer linear peptide, DWSSWVYRDPQT, and two 7-mer cysteine-constrained peptides, CIGNSNTLC and CTVRTSAEC that bound FR in the context of the phage particle. Synthesised lead peptide, CTVRTSAEC, bound specifically to FR and could be competitively inhibited with folic acid. To assess the capacity of the elucidated FR-binding oligopeptides to target OV to FR, we genetically incorporated the peptides into the HAdV-C5 fiber-knob HI loop including in vectors genetically ablated for hCAR interactions. Unfortunately, the recombinant vectors failed to efficiently target transduction via FR due to defective intracellular trafficking following entry via FR, indicating that whilst the peptides identified may have potential for applications for targeted drug delivery, they require additional refinement for targeted virotherapy applications.
机译:基于人腺病毒(HADV)载体的葡萄牙酵母病毒治疗(ov)对治疗晚期卵巢癌的治疗具有显着的希望,其中局部腹膜癌为肿瘤转移是可行的,绕过与血管内递送相关的许多复杂性。通过缺乏肿瘤选择性,患有基于致瘤的ov的疗效,其中初级受体HCAR通常在恶性转化期间通常下调。相反,叶酸受体α(FR)在卵巢癌细胞上高度表达,为病毒疗法提供了令人焦虑的肿瘤选择性靶向。在此,我们鉴定高亲和力FR结合的寡肽,用于遗传掺入到Hadv-C5载体中。生物烷鉴定为12-MEL线性肽,DWSSWVERDPQT和两个7-MEL半胱氨酸约束肽,CIGNSNTLC和CTVRTSAEC在噬菌体颗粒的上下文中结合FR。合成的铅肽,CTVRTSAEC,与FR的特异性结合,可以竞争性地抑制叶酸。为了评估阐明的FR结合寡肽以靶向ov至FR的能力,我们将肽掺入肽中,包括在遗传上烧蚀的载体中的vATV-C5纤维瘤HI环中进行HCAR相互作用。遗憾的是,重组载体未能有效地通过FR有效地靶向转导,因为在通过FR进入后缺陷细胞内运输缺陷,表明鉴定的肽可能具有用于靶向药物递送的潜力的潜力,因此它们需要额外的细化对靶向病毒疗法的额外细化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号